Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
Authors' conclusion
Real-world use of GLP-1RAs in youth with T2D is associated with decreased HbA1c levels, despite challenges with access and adherence. GLP-1RA treatment may reduce insulin doses for youth with T2D.
Study context
- Population
- Youth with T2D prescribed a GLP-1 RA at two academic paediatric diabetes centres before June 2022; median age 16.1 (IQR 13.9–18.0) years, 54% female, 56% non-Hispanic Black, 24% Hispanic, 77% public insurance
- Participants
- 136 participants
- Outcome
- Change in HbA1c from baseline
- Follow-up
- First (median 91 days) and second (median 190 days)
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
Median HbA1c, baseline to first follow-up · median 91 days
| Group | Value | Baseline median HbA1c |
|---|---|---|
| GLP-1 RA | median 7.6% | 7.9% |
GLP-1 RA
Valuemedian 7.6%
Baseline median HbA1c7.9%
- Median HbA1c decreased from 7.9% to 7.6%
- P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Median HbA1c, baseline to second follow-up · median 190 days | GLP-1 RA median 7.4% · baseline median HbA1c 8.4% |
- Median HbA1c, baseline to second follow-up: n = 83
Insulin prescribed, baseline to first follow-up
- Basal insulin 69% to 60%
- P = 0.008
- Prandial insulin 46% to 38%
- P = 0.03
HbA1c change per month (multivariable linear mixed effects model) · up to 6 months
- Mean decrease in HbA1c per month
- 0.09 (percentage points; 95% CI −0.15, −0.03; P = .005)
- Adjusted for sex, age, race/ethnicity, insurance, insulin regimen, metformin regimen, GLP-1 RA dosing frequency, BMI-Z
Original publication
Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obes Metab. Published 16 January 2024. doi:10. 1111/ dom. 15430
Composed by AI from the published abstract and checked against it. How Briefs are made →